Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06281977
Other study ID # ES613
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 8, 2024
Est. completion date August 1, 2027

Study information

Verified date June 2024
Source Ottawa Heart Institute Research Corporation
Contact F. Daniel Ramirez, MD MSc
Phone 613-696-7402
Email dramirez@ottawaheart.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.


Description:

Electrical storm (ES), defined as three or more sustained or treated ventricular arrhythmias in a 24-hour period, is a life-threatening condition that is associated with significant short- and long-term mortality. Autonomic dysfunction from increased sympathetic tone and the catecholamine surge from defibrillator shocks can precipitate recurrent ventricular arrhythmias and exacerbate ES. Although the mainstay of treatment are anti-arrhythmic drugs, sedative agents and procedures are commonly used to decrease sympathetic tone. These therapies have been studied in refractory ES but the benefit of early sedation remains unclear. Alpha-2 agonism with dexmedetomidine can provide conscious sedation without the need for mechanical ventilation. Dexmedetomidine has been found to reduce ventricular arrhythmia events in non-ES patients in the intensive care unit and in the peri-operative period. Its antiarrhythmic properties are thought to be due to catecholamine suppression, prolonging electrical refractory periods, and increasing vagal tone. Its rapid onset and favorable safety profile render alpha-2 agonism with dexmedetomidine a potentially valuable therapy for patients with ES. This study is a multi-centre, double-blinded, placebo-controlled, randomized trial that will evaluate the effectiveness of dexmedetomidine in the acute treatment of ES. Consecutive patients admitted to an intensive care unit will be randomized to receive dexmedetomidine or placebo at the time of presentation. The study drug will be titrated to a maintenance dose and continued for 48 hours before being weaned.


Recruitment information / eligibility

Status Recruiting
Enrollment 192
Est. completion date August 1, 2027
Est. primary completion date May 8, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment. Exclusion Criteria: - Refractory shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors - SCAI class D or E cardiogenic shock - Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment. - ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia. - Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater atrioventricular block in the absence of a pacemaker. - Pregnancy - Known dexmedetomidine allergy or intolerance - Inability to obtain consent from patient or substitute decision maker. - Patients who have received dexmedetomidine or clonidine during the 24 hours prior to randomization

Study Design


Intervention

Drug:
Dexmedetomidine
Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.
Normal saline
Programed as dexmedetomidine on infusion pump.

Locations

Country Name City State
Canada University of Ottawa Heart Institute Ottawa Ontario

Sponsors (1)

Lead Sponsor Collaborator
Ottawa Heart Institute Research Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome is a composite of the following: 1. All-cause in-hospital death AND/OR 2. Any in-hospital ventricular arrhythmia requiring treatment after study drug initiation. Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo Duration of index hospitalization - an average of 2 weeks
Secondary All-cause in-hospital death Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo Duration of index hospitalization - an average of 2 weeks
Secondary Ventricular arrhythmia requiring treatment after study drug initiation Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo Duration of index hospitalization - an average of 2 weeks
Secondary Resuscitated cardiac arrest after study drug initiation Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo Duration of index hospitalization - an average of 2 weeks
Secondary Renal failure requiring new initiation of renal replacement therapy after study drug initiation Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo Duration of index hospitalization - an average of 2 weeks
Secondary Intubation following study drug initiation Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo Duration of index hospitalization - an average of 2 weeks
Secondary Length of stay in the intensive care unit Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo Duration of index hospitalization - an average of 2 weeks
Secondary Length of stay in hospital Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo Duration of index hospitalization - an average of 2 weeks
Secondary Need for mechanical circulatory support device after study drug initiation Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo Duration of index hospitalization - an average of 2 weeks
Secondary Ventricular Arrhythmia requiring treatment only during active study drug treatment Defined as anytime the participant is receiving dexmedetomidine or normal saline placebo Duration of index hospitalization - an average of 2 weeks
Secondary Pacing or treatment with isoproterenol for treatment of bradyarrhythmia after study drug initiation. Defined as anytime after the participant starts receiving dexmedetomidine or normal saline placebo Duration of index hospitalization - an average of 2 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03453645 - Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation
Completed NCT05791032 - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study N/A
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Completed NCT04011631 - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System. N/A
Recruiting NCT03536052 - Ablation at Virtual-hEart pRedicted Targets for VT N/A
Not yet recruiting NCT06063811 - Ventricular Tachycardia Ablation in LVAD Patients
Enrolling by invitation NCT02962076 - Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia Early Phase 1
Not yet recruiting NCT02784912 - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation N/A
Completed NCT01791543 - Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia N/A
Terminated NCT02891863 - Low Energy Therapy to Convert Ventricular Tachycardias Phase 0
Terminated NCT01546207 - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia N/A
Completed NCT01294267 - Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation N/A
Terminated NCT00383799 - Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia Phase 4
Completed NCT04884100 - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening N/A
Completed NCT04642963 - Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular Tachycardia N/A
Recruiting NCT05377216 - Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation Early Phase 1
Not yet recruiting NCT04990089 - VIVO European Observational Registry
Completed NCT04065893 - Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy
Recruiting NCT03631303 - Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias
Recruiting NCT03611465 - Creation of a Pace-mapping Atlas on Healthy and Pathological Hearts N/A